Perrigo Claims Reckitt's Bid To Block Generic Mucinex Is "Baseless"
This article was originally published in The Tan Sheet
Executive Summary
Reckitt Benckiser's petition seeking to define specific bioequivalence standards for private-label versions of Mucinex OTC cough products, if followed, would push FDA to violate generic drug law, Perrigo argues
You may also be interested in...
FDA Denial Of Mucinex Petition Stops Reckitt's Bid To Delay Generics
FDA stymies Reckitt Benckiser's attempt to delay private label competition for Mucinex OTC cough products by rejecting the firm's request to redefine bioequivalence standards for guaifenesin generics
FDA Denial Of Mucinex Petition Stops Reckitt's Bid To Delay Generics
FDA stymies Reckitt Benckiser's attempt to delay private label competition for Mucinex OTC cough products by rejecting the firm's request to redefine bioequivalence standards for guaifenesin generics
FDA Denial Of Mucinex Petition Stops Reckitt's Bid To Delay Generics
FDA stymies Reckitt Benckiser's attempt to delay private label competition for Mucinex OTC cough products by rejecting the firm's request to redefine bioequivalence standards for guaifenesin generics